Navigation Links
Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
Date:11/3/2008

CALGARY, Nov. 3 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that it has achieved positive interim results in its U.K. combination REOLYSIN(R) and docetaxel clinical trial for patients with advanced cancers.

Prof. Hardev Pandha of the Royal Surrey Hospital, U.K., presented the results at the International Society for Biological Therapy of Cancer (iSBTC) annual meeting on November 1, 2008. The meeting was held in San Diego, California from October 31 - November 2, 2008.

Fourteen patients have been treated to date in the dose escalation portion of the trial and eleven patients are evaluable for response. The detailed results are summarized in the following table:

-------------------------------------------------------------------------

REOLYSIN Dose

Primary Tumour TCID(50) Cycles Best Response

-------------------------------------------------------------------------

Breast 1x10(10) 8 PR

CR in liver

-------------------------------------------------------------------------

Gastric 3x10(10) 8* PR

32% reduction in

lymph nodes

-------------------------------------------------------------------------

Mesothelioma 1x10(10) 6 Minor response

23% reduction in

lymph nodes

-------------------------------------------------------------------------

Prostate 3x10(9) 6 SD on scans

30% reduction in PSA

-------------------------------
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Paclitaxel/Carboplatin Results at iSBTc Annual Meeting
2. Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
3. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
4. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
5. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
6. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
8. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
9. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
10. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)... , NOVATO, Calif., Nov. 30 /PRNewswire-FirstC...N ) announced today that the Food and Drug Adminis...for 3,4-diaminopyridine (3,4-DAP), amifampridine p...Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has pre...U. Also, in October 2009, the Committee for Medic...
(Date:11/30/2009)... , BOSTON and COPENHAGEN, Nov. 30 /PRNewsw...announced today that the Harvard Medical School IC...ecognized as a MicroRNA Screening Center of Excell...dical School, and associated hospitals and institu...cule and RNAi libraries. ,, MicroRNAs are a nov...
(Date:11/30/2009)... , AMSTERDAM, N... world,s,leading publisher of scientific, medical ...ed a major re-launch of Embase, its comprehensive ...dexed records from more than 7,000,active, peer re... a key role in the advancement of new biomedical,a...
(Date:11/27/2009)... , DURHAM, N.C., Nov. 27 /PRNewswire/ ... will initiate water-soluble carbon nanotube-based...The water-soluble carbon nanotubes, which have fun...ation with cancer drugs, was developed in partners... conjugated carbon nanotubes serves as a drug deli...
Breaking Biology Technology:FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 2Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence 3Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 2Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers 3North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India 2
...hina, Jan. 14 /Xinhua-PRNewswire-FirstCall/ --,Chi...letin Board: CPHI),which develops, manufactures, a...oducts in China, today announced that it has retai...active and targeted investor,relations campaign. M...,collective team, will be advising the Company in ...
...he Institute for International,Research (IIR) has ...o lead,a workshop on actual case studies about way... using a Web-based integration of operations, achi...iciencies. The workshop will be,held 1:30 p.m. Wed...age,Congress in Scottsdale, Ariz. For registration...
...1 Barr Pharmaceuticals,Inc. (NYSE: BRL ) today c...c., has initiated a challenge of the patent listed...ts Namenda(R) (memantine,hydrochloride) tablets, 5... Application (ANDA) containing a,paragraph IV cert....S. Food,& Drug Administration (FDA) on October 16...
Other Biology Technology:China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program 2China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program 3MedicareCRM(TM) to Speak at IIR Medicare Advantage Congress 2Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg 2Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg 3
(Date:11/30/2009)...ing your extended family over the holidays was slo...the December 2009 print issue of the Journal of L...s that you might be right. Here,s the good news: r...new treatments that help keep autoimmune diseases ...hat,s because researchers from the University of C...
(Date:11/26/2009)...red deer have been caught in the hunters, sights f... than decorative. They are lethal weapons that sta... The University of York, UK, has been intrigued by... century and has become fascinated by the mechanic...llaboration with Tomas Landete-Castillejos at the ...
(Date:11/26/2009)...coccus Aureus ) and other drug-resistant bacteria ...prototype devices have been developed to offer saf...s. , Two prototype devices have been developed: ...g. hands and feet) in hospitals and public spaces ...er to shoot bacteria-killing agents into infested ...
Breaking Biology News(10 mins):Seeing family for the holidays? Scientists discover how the stress might kill you 2Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Walk for Parkinson 26apos 3Bs Disease Scheduled for Saturday September 19 2009 53615 1Walk for Parkinson 26apos 3Bs Disease Scheduled for Saturday September 19 2009 53615 2Walk for Parkinson 26apos 3Bs Disease Scheduled for Saturday September 19 2009 53615 3Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 1Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 13358 2Nile Therapeutics Inc Announces Dosing of First Patient in Phase 2 Study of CD NP for the Treatment of Acute Heart Failure 13356 1Nile Therapeutics Inc Announces Dosing of First Patient in Phase 2 Study of CD NP for the Treatment of Acute Heart Failure 13356 2Nile Therapeutics Inc Announces Dosing of First Patient in Phase 2 Study of CD NP for the Treatment of Acute Heart Failure 13356 3
...e may help people regain strength and normal use o... a University of California, Irvine study. , St...oved ability to grasp and release objects after th...tic Device (HOWARD). Each patient had at least mod...e right hand, although the affected hands were nei...
...a ?a form of cancer associated with asbestos expos... a combination of two cancer drugs, a large multic...essive form of cancer that occurs in the lining of...exposure to asbestos. There is no known cure. ,...isplatin ?along with the vitamin supplements folic...
...activity in the brain,s prefrontal cortex as subje...ions, researchers have been able to distinguish co...bjects, different plans. The findings, reported by... the Max Planck Institute for Human Cognitive and ...ent Biology online on February 8th. , Past researc...
Other Biology News:Robotic therapy helps restore hand use after stroke 2Robotic therapy helps restore hand use after stroke 3Chemo combination improves survival in asbestos-related cancer 2Chemo combination improves survival in asbestos-related cancer 3Reading hidden intentions in the human brain 2
...ease III digests duplex DNA in a 3'-> 5' direction...stretches of single-stranded DNA. Under defined re...III proceeds at a uniform rate yielding predictabl...onucleolytic excision of deoxyribonucleotides by E...
RNase H from Roche Applied Science
Goat Anti-Human Haptoglobin Polyclonal Antibody, Unconjugated from Abcam
Rat Anti-STENOTROPHOMONAS MALTOPHILIA Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: